Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its ...